# A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

> **NCT07099898** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 420 (estimated)

## Conditions studied

- Neoplasms, Lung

## Interventions

- **BIOLOGICAL:** Ris-Rez
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT07099898
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2027-11-05
- **Final completion:** 2029-09-28
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07099898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07099898, "A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07099898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*